HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.

Abstract
Tumour necrosis factor-alpha (TNF) has been used in the clinic for more than 10 years in an isolated limb perfusion (ILP). However, intra-tumoural expression of TNF receptor-1 (TNF-R1) and TNF-R1 upregulating factors are unknown. We determined the expression of TNF-R1, proEMAP and endothelial monocyte-activating polypeptide-II (EMAP-II) before and after ILP and evaluated this against clinical response. Tumour biopsies were taken before and after ILP of patients (n = 27) with advanced sarcoma or metastatic melanoma. Biopsies were randomly analysed by western blotting for proEMAP/EMAP-II and TNF-R1 expression. Appropriate melanoma biopsies were stained for EMAP-II, TNF-R1, CD31 and CD68. For melanomas we found that an up-regulation of EMAP-II, in contrast to proEMAP or TNF-R1, directly after ILP significantly correlated with a complete tumour response. No correlation was found for sarcoma patients. In a comparative analysis we found that the overall proEMAP and EMAP-II expression was higher in melanoma as compared to sarcoma cases and measurements in cell lines revealed high proEMAP expression by melanoma cells. We report high EMAP-II expression by endothelial cells and association with macrophages. In addition, macrophages are recruited to vessel-remnants after ILP. An upregulation of EMAP-II directly after ILP of melanoma patients correlates with and might predict a complete response to TNF-based ILP. The association of macrophages with EMAP-II expression and vascular damage suggests a role for EMAP-II in regulating the TNF-based anti-tumour effects observed with an ILP. Analysis of EMAP-II expression in melanoma biopsies should be implemented in the ILP procedure.
AuthorsRemco van Horssen, Joost A P Rens, Flavia Brunstein, Veronique Guns, Marjon van Gils, Timo L M Ten Hagen, Alexander M M Eggermont
JournalInternational journal of cancer. Journal international du cancer (Int J Cancer) Vol. 119 Issue 6 Pg. 1481-90 (Sep 15 2006) ISSN: 0020-7136 [Print] United States
PMID16615114 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Cytokines
  • Neoplasm Proteins
  • RNA-Binding Proteins
  • Receptors, Tumor Necrosis Factor, Type I
  • Tumor Necrosis Factor-alpha
  • small inducible cytokine subfamily E, member 1
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Antineoplastic Agents (administration & dosage)
  • Chemotherapy, Cancer, Regional Perfusion (methods)
  • Cytokines (metabolism)
  • Extremities
  • Female
  • Humans
  • Male
  • Melanoma (secondary, therapy)
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Neoplasm Proteins (metabolism)
  • Perfusion
  • RNA-Binding Proteins (metabolism)
  • Receptors, Tumor Necrosis Factor, Type I (metabolism)
  • Sarcoma (therapy)
  • Skin Neoplasms (secondary, therapy)
  • Transfection (methods)
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha (administration & dosage)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: